GlassScriptPhysician profile
Sherri S Arledge
NPI 1881805406
$19,232.46
in general payments reported to CMS, 2019-2025
82 companies · $3,265 in 2025
The $3,265 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,955 · 2020: $1,609 · 2021: $2,620 · 2022: $3,049 · 2023: $2,998 · 2024: $2,737 · 2025: $3,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,725 · Consulting Fee: $175 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,724.56 |
| Consulting Fee | $175.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,898.24 | 2019-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $1,404.89 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,334.58 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Astellas Pharma US INC | $1,055.99 | 2019-2025 | Xospata, Vyloy, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $944.99 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $869.18 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Amgen INC. | $867.85 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Pfizer INC. | $831.71 | 2019-2025 | |
| Incyte Corporation | $770.01 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $678.50 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $675.20 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $667.45 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Celgene Corporation | $589.46 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Alexion Pharmaceuticals, INC. | $450.39 | 2021-2025 | Ultomiris, Soliris |
| Eisai INC. | $444.91 | 2020-2025 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $333.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $321.68 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Regeneron Healthcare Solutions, INC. | $313.24 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $297.78 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Ipsen Biopharmaceuticals, INC | $269.63 | 2019-2025 | Onivyde, Somatuline Depot |
| Exelixis INC. | $257.93 | 2019-2025 | Cabometyx |
| Abbvie INC. | $255.13 | 2019-2025 | Venclexta |
| Myriad Genetic Laboratories, INC. | $234.68 | 2022-2024 | Myrisk |
| Blueprint Medicines Corporation | $176.97 | 2020-2024 | Ayvakit |
| Array Biopharma INC | $168.78 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.90 | 2021-2025 | |
| Puma Biotechnology, INC. | $155.81 | 2019-2024 | Nerlynx |
| Seagen INC. | $149.15 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Beigene USA, INC. | $147.87 | 2020-2025 | Brukinsa, Tevimbra |
| Springworks Therapeutics, INC. | $138.68 | 2024-2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $124.39 | 2021-2025 | Qinlock, Romvimza |
| Emd Serono, INC. | $118.91 | 2019-2025 | Tepmetko |
| Gilead Sciences, INC. | $111.28 | 2019-2025 | Trodelvy |
| Kyowa Kirin, INC. | $103.63 | 2019-2021 | |
| Tg Therapeutics, INC. | $99.66 | 2021-2022 | |
| Pharmaessentia USA Corporation | $92.10 | 2023-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $82.78 | 2019-2023 | |
| Beone Medicines USA, INC. | $77.54 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $72.40 | 2019-2021 | |
| Kite Pharma, INC. | $69.69 | 2021-2025 | Yescarta |
| Stemline Therapeutics INC. | $68.25 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $68.21 | 2023-2025 | Zoladex |
| Coherus Oncology, INC. | $64.77 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $56.29 | 2023-2024 | Clonoseq |
| Genmab U.S., INC. | $55.32 | 2024-2025 | Epkinly |
| Acceleron Pharma, INC. | $55.31 | 2020 | |
| Dova Pharmaceuticals | $54.16 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $52.59 | 2025 | Monoferric |
| Sumitomo Pharma America, INC. | $50.08 | 2023-2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $49.01 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $48.84 | 2020-2024 | Xpovio |
| Aurobindo Pharma USA, INC. | $47.88 | 2019-2020 | |
| Morphosys, US INC. | $46.45 | 2022-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $44.25 | 2019-2025 | Tavalisse, Gavreto, Rezlidhia |
| Epizyme, INC. | $42.51 | 2020-2022 | |
| Heron Therapeutics, INC. | $40.99 | 2022 | |
| Sobi, INC | $39.90 | 2022-2024 | |
| Acrotech Biopharma INC. | $37.02 | 2023-2025 | Beleodaq |
| G1 Therapeutics, INC. | $35.12 | 2022-2023 | Cosela |
| Adc Therapeutics America, INC. | $34.71 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $31.04 | 2024-2025 | Sancuso |
| Azurity Pharmaceuticals, INC. | $30.86 | 2024-2025 | Danziten, Vivimusta |
| Mirati Therapeutics, INC. | $29.71 | 2023-2024 | Krazati |
| Apellis Pharmaceuticals, INC. | $28.70 | 2023-2024 | Empaveli |
| Secura Bio, INC. | $25.58 | 2020-2021 | |
| Tempus Ai, INC | $25.49 | 2024 | |
| Immunogen, INC. | $24.63 | 2023 | Elahere |
| Tesaro, INC. | $23.63 | 2019 | |
| Veracyte, INC. | $20.41 | 2023 | |
| Sanofi-Aventis U.S. LLC | $19.77 | 2021 | |
| Caris Mpi, INC. | $18.93 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $17.93 | 2024 | Rolvedon |
| Lexicon Pharmaceuticals, INC. | $17.57 | 2020 | |
| Eusa Pharma (US) LLC | $16.81 | 2019 | |
| Servier Pharmaceuticals LLC | $15.82 | 2025 | |
| Progenics Pharmaceuticals, INC. | $14.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.12 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.64 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.35 | 2019 | |
| Verastem, INC. | $11.96 | 2020 | |
| Clovis Oncology, INC. | $3.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $574Enhertu $536Reblozyl $360Opdivo $336Kisqali $299Lynparza $292Scemblix $261Ultomiris $257Libtayo $240Verzenio $229Venclexta $228Jaypirca $226Myrisk $222Lenvima $195Jakafi $171Monjuvi $153Iclusig $151Xtandi $151Padcev $147Cabometyx $143Sarclisa $141Retevmo $137Brukinsa $132Imfinzi $122Ogsiveo $122Welireg $117Tecentriq $115Pomalyst $114Tukysa $111Xospata $101Vyloy $97.11Erleada $97.09Calquence $95.15Braftovi $94.57Mektovi $94.57Darzalex $92.53Besremi $92.10Jemperli $91.55Onivyde $89.03Tasigna $86.96Adcetris $86.28Polivy $83.60Ojjaara $79.38Inlyta $73.16Orgovyx $72.95Imbruvica $72.44Rybrevant $72.11Ibrance $70.96Lorbrena $70.61Orserdu $68.25Zoladex $68.21Talvey $68.20Tecvayli $68.15Balversa $68.02Pluvicto $66.85Elrexfio $66.36Akeega $64.31Piqray $59.91Trodelvy $59.55Clonoseq $56.29Talzenna $55.38Epkinly $55.32Monoferric $52.59Vectibix $50.07Nplate $50.07Xgeva $50.07Qinlock $49.15Bosulif $48.72Keytruda Qlex $47.52Udenyca $45.80Ayvakit $45.74Zynyz $43.13Promacta $41.77Paxlovid $40.65Opdualag $37.82Beleodaq $37.02Fabhalta $35.20Mekinist $34.97Tevimbra $34.74Zejula $34.37Xalkori $32.88Rezlidhia $31.22Tavalisse $31.22Gavreto $31.22Sancuso $31.04Carvykti $30.52Datroway $29.84Krazati $29.71Oxbryta $29.54Empaveli $28.70Lumakras $28.27Injectafer $26.06Elahere $24.63Soliris $24.10Doptelet $23.84Comirnaty $22.87Columvi $22.37Lunsumio $22.37Fruzaqla $21.86Fotivda $20.38
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Arledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.